Project Grant R01HL169780
Award Date
8/1/24
Completion Date
5/31/29
Dollars Obligated
$691K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Chicago, IL 60611, USA
Similar Awards
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), part of the Cardiovascular Diseases Research program (CFDA 93.837), provides $117,000 to the University of Colorado-Denver to conduct secondary analysis of 3D echocardiography images of the right ventricle. The goal is to develop computational methods using machine learning to analyze 3D strain parameters that can better detect early signs of right ventricular dysfunction in pulmonary arterial...
The National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH), awarded a $522,794 Project Grant (CFDA 93.837 Cardiovascular Diseases Research) to the University of Illinois to study the role of the voltage-gated proton channel HV1 in the development of pulmonary hypertension. The research aims to delineate how HV1 contributes to the pathogenesis of pulmonary hypertension, including examining molecular mechanisms and determining the potential for HV1...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $167,940 Project Grant (CFDA 93.837 - Cardiovascular Diseases Research) to The Children's Hospital Corporation (doing business as Boston Children's Hospital) with a project period from Sep 20, 2024 to Aug 31, 2029. The grant aims to develop a novel mouse model of flow-induced pulmonary hypertension (PH) that better represents the physiological conditions observed in patients with congenital heart disease. Additionally, the project...
This $812,189 Project Grant award, provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), supports research to better understand pulmonary hypertension in patients with chronic obstructive pulmonary disease (COPD) using advanced clinical CT imaging. The research team at Brigham & Women's Hospital, which is part of the Mass General Brigham healthcare system, will leverage data from several NIH-funded cohorts to...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $656,751 to Third Coast Dynamics, Inc. to develop an artificial intelligence-based platform called "TCDFLOW" that can derive 4D hemodynamic data from routine clinical anatomic images. This will address limitations of current 4D flow MRI techniques, which require specialized equipment and expertise, by enabling the...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $298,368 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Link Medical LLC, a for-profit limited liability company located in Chelsea, Michigan. The grant supports the development of a novel catheter-based technology to treat mitral valve regurgitation, a common cardiovascular condition. The project aims to optimize the device design and procedure through bench testing, followed by conducting in vivo...
The University of Southern California received a $677,635 Project Grant (R56HL173809) from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837). The grant aims to develop a novel generation of high-speed 4D echocardiography systems with adjustable multi-planar acquisition capabilities. The project will leverage broadband matrix array transducer technology, multi-line transmit focusing, and coherence-based beamforming to enable...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $1,806,634 Project Grant (CFDA 93.837 - Cardiovascular Diseases Research) to the University of California, San Diego to study the NOTCH3 extracellular domain (NOTCH3 ECD) as a serum biomarker for pulmonary arterial hypertension (PAH). The goal is to determine if NOTCH3 ECD levels in patient serum can reliably predict PAH disease progression and severity, regardless of drug regimens. The research aims to develop a simple blood test...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $321,363 to Nucleusrx, Inc. to develop and test a virtual care platform and remote intervention tool targeting post-acute care heart failure (HF) patients. The goal is to create a solution that enables healthcare providers to implement a safe discharge transition plan from hospital to home, while allowing rapid optimization of...
This $148,548 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research (CFDA 93.837) program supports the development of a 3D bioprinted heart model to investigate how dysregulated biomechanical forces impede cardiac proliferation in hypoplastic left heart syndrome (HLHS). The award will enable researchers at the Research Institute at Nationwide Children's Hospital to create a 3D model patterned with induced pluripotent stem...